Literature DB >> 20729729

Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials.

Petros Kopterides1, Ilias I Siempos, Iraklis Tsangaris, Argirios Tsantes, Apostolos Armaganidis.   

Abstract

OBJECTIVE: There is increasing interest for strategies that could curtail antibiotic resistance in the critical care setting. We sought to determine the effectiveness and safety of procalcitonin-guided algorithms in the management of septic patients in the intensive care unit. DATA SOURCES: MEDLINE, Scopus, Cochrane Central Register of Controlled Trials (through April 2010), reference lists of retrieved publications, and queries of corresponding authors. No language restrictions were applied. STUDY SELECTION: We included only randomized controlled studies reporting on antibiotic use and clinical outcomes of intensive care unit patients managed with a procalcitonin-guided algorithm or according to routine practice. DATA EXTRACTION: Data on study characteristics, interventions, and outcomes were retrieved by two independent reviewers. Pooled odds ratios, weighted mean differences, and 95% confidence intervals were calculated by implementing both the Mantel-Haenszel fixed effect model and the DerSimonian-Laird random effects model. DATA SYNTHESIS: Seven randomized controlled studies involving 1131 intensive care unit patients (adults = 1010; neonates = 121) were included. In comparison with routine practice, the implementation of procalcitonin-guided algorithms decreased the duration of antibiotic therapy for the first episode of infection by approximately 2 days (weighted mean difference = -2.36 days; 95% confidence interval, -3.11 to -1.61) and the total duration of antibiotic treatment by 4 days (fixed effect model: weighted mean difference: -4.19 days; 95% confidence interval, -4.98 to -3.39). The comparison between the procalcitonin and the routine practice group was not associated with any apparent adverse clinical outcome: 28-day mortality (fixed effect model: odds ratio = 0.93; 95% confidence interval, 0.69 to 1.26), intensive care unit length of stay (fixed effect model: pooled weighted mean difference = -0.49 days, 95% confidence interval, -1.55 to 0.57), and relapsed/persistent infection rate (fixed effect model: odds ratio = 0.97; 95% confidence interval, 0.56 to 1.69).
CONCLUSIONS: The implementation of a procalcitonin-based algorithm may reduce antibiotic exposure in critically ill, septic patients without compromising clinical outcomes, but further research is necessary before the wide adoption of this strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20729729     DOI: 10.1097/CCM.0b013e3181f17bf9

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  83 in total

Review 1.  An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.

Authors:  Dimitrios K Matthaiou; Georgia Ntani; Marina Kontogiorgi; Garyfallia Poulakou; Apostolos Armaganidis; George Dimopoulos
Journal:  Intensive Care Med       Date:  2012-04-27       Impact factor: 17.440

Review 2.  Healthcare-associated infection prevention in pediatric intensive care units: a review.

Authors:  N Joram; L de Saint Blanquat; D Stamm; E Launay; C Gras-Le Guen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-01       Impact factor: 3.267

Review 3.  Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections.

Authors:  Hui Li; Yi-Feng Luo; Timothy S Blackwell; Can-Mao Xie
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

4.  Implementation of a procalcitonin-guided algorithm for antibiotic therapy in the burn intensive care unit.

Authors:  A Lavrentieva; P Kontou; V Soulountsi; J Kioumis; O Chrysou; M Bitzani
Journal:  Ann Burns Fire Disasters       Date:  2015-09-30

Review 5.  Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.

Authors:  Marin H Kollef; Yoav Golan; Scott T Micek; Andrew F Shorr; Marcos I Restrepo
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

6.  The role of procalcitonin in respiratory infections.

Authors:  Laura Certain; Philipp Schuetz
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

7.  Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis.

Authors:  A Hohn; B Heising; S Hertel; G Baumgarten; M Hochreiter; S Schroeder
Journal:  Infection       Date:  2015-01-15       Impact factor: 3.553

8.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

9.  Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States.

Authors:  Robert A Balk; Sameer S Kadri; Zhun Cao; Scott B Robinson; Craig Lipkin; Samuel A Bozzette
Journal:  Chest       Date:  2016-08-25       Impact factor: 9.410

10.  Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.

Authors:  Tolga Sursal; Deborah J Stearns-Kurosawa; Kiyoshi Itagaki; Sun-Young Oh; Shiqin Sun; Shinichiro Kurosawa; Carl J Hauser
Journal:  Shock       Date:  2013-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.